Search

Objective：To explore the expression and clinical significance of dishevelled-associated activator of morphogenesis 1 (DAAM1)and DAAM2 in pancreatic cancer. Methods：Pancreatic cancer tissue microarray(TMA, HPanA120Su02)was obtained from OUTDO BioTech(Shanghai), including 66 tumor samples and 54 adjacent samples. Immunohistochemistry(IHC)was used to detect the expression levels of DAAM1 and DAAM2 in pancreatic cancer and para-tumor tissues. Expression profiles of DAAM1, DAAM2, PDL1 and other immune checkpoints were downloaded from the TCGA database. Statistical methods, such as t-test, χ2 test, log-rank test and correlation analysis, were used to analyze the differential expression of DAAM1 and DAAM2 between tumor and adjacent samples, the co -expression pattern of DAAM1 and DAAM2, and their association with clinicopathological parameters, prognosis and expression levels of immune checkpoints. Results：Compared with the adjacent tissues, the expression of DAAM1 and DAAM2 in pancreatic cancer were significantly upregulated (P ＜ 0.001), and the expression levels of DAAM1 and DAAM2 in pancreatic cancer tissue were significantly positively correlated (P ＜ 0.001). There was marginally significant in the correlation between DAAM1 expression and tumor differentiation (P=0.062)and survival status (P=0.061), but DAAM1 expression was not significantly correlated with other clinic-pathological parameters (P ＞ 0.05). However, DAAM2 expression was not related to any clinic-pathological parameters (P ＞ 0.05). In the TCGA database, DAAM1 and DAAM2 were positively correlated with the expression levels of multiple immune checkpoints (P ＜ 0.001). Conclusion：The expression of DAAM1 and DAAM2 are significantly upregulated in pancreatic cancer, and positively correlated with the expression levels of multiple immune checkpoints, which may be a critical regulatory factor for the oncogenesis, progression and immune evasion in pancreatic cancer. [ABSTRACT FROM AUTHOR]